Mealey's (October 10, 2018, 11:32 AM EDT) -- WASHINGTON, D.C. — The same day that Teva Pharmaceuticals USA Inc. filed its respondent brief in a U.S. Supreme Court dispute over what triggers the on-sale bar in the patent application process, the high court in its Oct. 9 order list granted the U.S. Department of Justice’s petition to participate in upcoming Dec. 4 oral arguments as amicus curiae (Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc., et al., No. 17-1229, U.S. Sup.)....